Literature DB >> 19705186

The role of pleurodesis in the management of chylous pleural effusion after surgery for congenital heart disease.

Poomiporn Katanyuwong1, Joseph Dearani, David Driscoll.   

Abstract

This study aimed to determine the incidence and outcome of postoperative chylous pleural effusion as well as the efficacy of pleurodesis for its management after surgery for congenital heart disease. Medical and surgical databases were used to identify all patients who had surgery for congenital heart disease and subsequently experienced postoperative chylous pleural effusion. Medical records were reviewed and daily chest drainage and management strategies were recorded. From January 2000 to June 2006, 1,166 cardiac operations were followed by 19 cases of chylous pleural effusion, for an incidence of 1.6%. The diagnosis was made a mean of 9 days after the operation. The patients were divided into two groups according to treatment strategy. Group 1 included 9 patients who had received only conventional medical treatment consisting of parenteral nutrition and/or medium-chain triglyceride formula and/or a low-fat diet and/or somatostatin. Group 2 included 10 patients who initially received conventional medical treatment, then subsequently received chemical or mechanical pleurodesis. The amount of the chylous drainage was significantly less in group 1 (14 ml/kg/day) than in group 2 (24 ml/kg/day) (P < 0.05), suggesting a more severe problem in group 2. For group 2, the amount of drainage was significantly less after chemical or mechanical pleurodesis (8 vs 24 ml/kg/day; P < 0.05) than before. Seven patients (70%) responded favorably to the first pleurodesis, and two patients (20%) required more than one pleurodesis. One patient (10%) did not respond to pleurodesis but was treated successfully with thoracic duct ligation. There were no deaths. Pleurodesis is a safe and effective method for treating chylous effusion after surgical treatment of congenital heart disease, especially after failed conservative treatment. However, some patients may need more than one pleurodesis.

Entities:  

Mesh:

Year:  2009        PMID: 19705186     DOI: 10.1007/s00246-009-9515-1

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  18 in total

1.  Octreotide in the management of postoperative chylothorax.

Authors:  L Rosti; F De Battisti; G Butera; S Cirri; M Chessa; A Delogu; M Drago; A Giamberti; G Pomè; M Carminati; A Frigiola
Journal:  Pediatr Cardiol       Date:  2005 Jul-Aug       Impact factor: 1.655

2.  Etiology and management of pediatric chylothorax.

Authors:  M Beghetti; G La Scala; D Belli; P Bugmann; A Kalangos; C Le Coultre
Journal:  J Pediatr       Date:  2000-05       Impact factor: 4.406

Review 3.  Chylothorax in the neonatal period.

Authors:  H L van Straaten; L J Gerards; T G Krediet
Journal:  Eur J Pediatr       Date:  1993-01       Impact factor: 3.183

4.  Surgical treatment of chylothorax caused by cardiothoracic surgery in children.

Authors:  Chin-Su Liu; Hsin-Lin Tsai; Tai-Wai Chin; Chou-Fu Wei
Journal:  J Chin Med Assoc       Date:  2005-05       Impact factor: 2.743

5.  Postoperative chylothorax after cardiothoracic surgery in children.

Authors:  Emily H Chan; Jennifer L Russell; William G Williams; Glen S Van Arsdell; John G Coles; Brian W McCrindle
Journal:  Ann Thorac Surg       Date:  2005-11       Impact factor: 4.330

6.  Treatment of refractory chylothorax with externalized pleuroperitoneal shunts in children.

Authors:  A B Wolff; M L Silen; E R Kokoska; B M Rodgers
Journal:  Ann Thorac Surg       Date:  1999-09       Impact factor: 4.330

Review 7.  Pleurodesis for malignant pleural effusions.

Authors:  P Shaw; R Agarwal
Journal:  Cochrane Database Syst Rev       Date:  2004

Review 8.  Use of Monogen for pediatric postoperative chylothorax.

Authors:  Barbara E Cormack; Nigel J Wilson; Kirsten Finucane; Teena M West
Journal:  Ann Thorac Surg       Date:  2004-01       Impact factor: 4.330

9.  Management of pediatric postoperative chylothorax.

Authors:  S J Bond; P C Guzzetta; M L Snyder; J G Randolph
Journal:  Ann Thorac Surg       Date:  1993-09       Impact factor: 4.330

10.  Experimental protein-losing gastroenteropathy: role of tissue plasminogen activator.

Authors:  M Kondo; K Nakanishi; T Bamba; K Hosokawa; M Masuda
Journal:  Gastroenterology       Date:  1976-10       Impact factor: 22.682

View more
  2 in total

1.  Factors Associated with Readmission of Patients with Congenital Heart Disease in a Swiss University Hospital.

Authors:  Morgane Chave; Pedro Marques-Vidal
Journal:  Pediatr Cardiol       Date:  2017-02-02       Impact factor: 1.655

2.  Successful pleurodesis with OK-432 in preterm infants with persistent pleural effusion.

Authors:  Jeong Eun Kim; Chul Lee; Kook In Park; Min Soo Park; Ran Namgung; In Kyu Park
Journal:  Korean J Pediatr       Date:  2012-05-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.